Empagliflozin inhibits neointimal hyperplasia through attenuating endothelial-to-mesenchymal transition via TAK-1/NF-κB pathway
Zhang W, Li X, Li M, He H, Yang C, Wang M, Liu D, Zhang L, Shu C. Empagliflozin inhibits neointimal hyperplasia through attenuating endothelial-to-mesenchymal transition via TAK-1/NF-κB pathway. European Journal Of Pharmacology 2023, 954: 175826. PMID: 37321472, DOI: 10.1016/j.ejphar.2023.175826.Peer-Reviewed Original ResearchConceptsNeointimal hyperplasiaEmpagliflozin treatmentTreatment groupsControl groupExpression levelsFSP-1NF-κB expression levelsTAK-1Western blottingCarotid ligation injuryInflammation-induced EndMTKi-67-positive cellsP-NF-κBMale C57BL/6J miceInhibits Neointimal HyperplasiaVascular neointimal hyperplasiaInflammatory gene mRNA expressionNF-κB pathwayNF-κB signalingMRNA expression levelsGene mRNA expressionVehicle treatmentArtery ligationLigation injuryInflammatory cells